SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Closure Medical (CLSR) fomerly Tri-Point Medical (TPMC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tuan Phan who wrote (93)1/31/1998 12:40:00 PM
From: David S.  Read Replies (1) of 184
 
Lehman stating that their estimates are above street estimates is not true. do more research. The success of Closure's product in Europe basically is really bad - you may say it's a tough call since it was only approved last year, but doctors in Europe have used similar products for a time prior to this being sold there, and sales in Europe for closure's product are way below prior expectations. If you look at the number of suture procedures done per year in the US and play with those numbers to arrive at some percentage that this product can replace, you come up with numbers that simply do not justify the current stock price. It is a situation similar to that of Organogenesis and Advanced Tissue Science. Getting approval is one thing, but having a market potential that is out of whack with a stock price is another. It is not Closure's fault that the stock is where it is, so I am not saying they are bad people or anything, it's just what sometimes happens in the stock market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News